Calcium channel blockers are a common cause of poisoning and are associated with high mortality in affected patients.
The condition affects women nine times as much as men.
Detailed price information for Milestone Pharmaceuticals Inc (MIST-Q) from The Globe and Mail including charting and trades.
Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that a moderated ...
A health explainer details how specific foods and beverages interact with blood pressure therapy, emphasizing safety ...
RAAS inhibitors outperform CCBs in paediatric CKD, lowering kidney failure risk. Discover how this real-world study could shape first-line treatment. Read more.
The study included 64 patients and was conducted in two segments.
If Kerendia secures a label expansion, it would become available to more than half of the overall CKD patient population who ...
FDA approval of CARDAMYST represents first new option in 30 years for the more than two million patients with PSVTParticipants using CARDAMYST in clinical studies were 2x more likely to convert sympto ...
A new study shows that people with high blood pressure can lower their risk of heart disease and type 2 diabetes, and may ...